A plateau feels like the medicine stopped.
Sometimes it means the care plan has moved from loss to maintenance.
In STEP 5, adults with obesity or overweight plus a weight-related condition, without diabetes, took semaglutide 2.4 mg or placebo for 104 weeks. Mean weight change was -15.2% with semaglutide versus -2.6% with placebo. [1]
That is long-term treatment, not a 30-day challenge.
These are prescription medicines. A clinician should review dose, side effects, and long-term access before changing the plan.
Plateaus are built into chronic weight care
Weight loss slows as body weight changes.
Food intake, side effects, missed doses, dose escalation, muscle mass, sleep, alcohol, medications, menopause symptoms, and lower daily movement can all affect the curve.
Tirzepatide trials make the maintenance point even clearer. In SURMOUNT-4, participants lost a mean 20.9% during a 36-week tirzepatide lead-in. Those who continued tirzepatide lost an additional 5.5% from week 36 to week 88, while those switched to placebo regained 14.0%. [2]
That is not a willpower story.
It is chronic treatment physiology.
SURMOUNT-1 also found mean weight loss of 15.0% to 20.9% at 72 weeks across tirzepatide doses, versus 3.1% with placebo. [3]
STEP 4 makes the same point for semaglutide continuation. Adults who continued semaglutide after a run-in period kept losing weight, while those switched to placebo regained weight. [4]
How to tell maintenance from a stalled plan
A useful plateau review starts with the trend, not one weigh-in. Holding a lower weight for several months after a clinically meaningful loss can be a good outcome. The question is whether the current plan still protects health: waist, blood pressure, three-month blood sugar marker, lipids, sleep apnea symptoms, joint pain, strength, and daily function can matter more than another fast drop on the scale.
A stalled plan looks different. It may include missed doses because the medicine is unavailable or unaffordable, dose escalation that cannot continue because of side effects, constipation or reflux that makes eating poorly, very low protein intake, falling strength, or regain after stopping. Those patterns point to different next steps. Some require side-effect management, some require nutrition and strength support, and some require a medication-access or long-term maintenance conversation.
What to review at a plateau
| Question | Why it matters |
|---|---|
| Is the dose tolerated? | Nausea, reflux, constipation, or low intake can limit safe escalation. |
| Is protein adequate? | Lean-mass loss matters more after menopause. |
| Is resistance training present? | Strength work helps protect function during weight loss. |
| Are other medicines fighting the plan? | Steroids, some antidepressants, insulin, and other drugs can affect weight. |
| Is maintenance acceptable? | Holding a 10% to 20% loss may still be clinically meaningful. |
Who fits a maintenance plan?
Maintenance may be the better fit when weight loss has slowed but health markers, waist, mobility, appetite control, sleep, or joint symptoms have improved. It can also fit when further dose escalation would worsen nausea, reflux, constipation, low intake, cost stress, or lean-mass risk.
A plateau needs more review when weight is rising quickly, side effects are driving under-eating, protein intake has collapsed, strength is falling, mood is worsening, or the patient is skipping doses because the plan is unaffordable. Those are not moral failures. They are care-plan signals.
Decision checkpoint: what changes the plan
| Signal | Why it changes the plan | What to do next |
|---|---|---|
| Dose escalation is causing worsening nausea, constipation, reflux, or low intake | Titration is a safety and adherence decision, not just a calendar event. | Review dose timing, hydration, bowel plan, nutrition, and whether escalation should wait. |
| Severe abdominal pain, repeated vomiting, dehydration, or gallbladder-type pain | Labels treat pancreatitis, gallbladder disease, kidney injury from volume depletion, and severe gastrointestinal reactions as warning-level issues. | Ask for clinician instructions rather than self-adjusting or pushing through. |
| Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 | glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 labels include boxed-warning and contraindication language for this history. | Do not treat eligibility as a weight-only decision. |
| Diabetes medicines, blood-pressure medicines, or procedure plans are involved | Appetite, glucose, fluid status, delayed gastric emptying, and anesthesia planning can interact. | Put the medication list, last dose date, symptoms, and procedure timing in one plan. |
| A compounded, research-use, or self-measured product is being considered | Product source and dose accuracy become part of the risk, not a minor logistics issue. | Anchor the discussion to approved labels and clinician monitoring. |
Evidence boundary
The point, for anyone weighing realistic weight expectations, is not simply that glucagon-like peptide-1 medicines can work. The distinction that matters more for a weight-loss plateau is between trial efficacy and patient-specific fit. For the maintenance phase, the product labels themselves already set out contraindications, warnings, escalation, product-specific adverse reactions, pregnancy cautions, hypoglycemia risk with diabetes medicines, kidney-dehydration monitoring, gallbladder concerns, pancreatitis symptoms, and procedure disclosure. [5] [6]
It matters especially after menopause for realistic weight expectations, when weight loss can overlap with constipation, reflux, gallbladder history, kidney vulnerability during dehydration, muscle and bone preservation, sleep apnea, diabetes prevention, and medication changes. A page on a weight-loss plateau that ignores those tradeoffs may still rank for a query, but it does not help the reader make a safer decision.
The useful job of the evidence around the maintenance phase is to split three questions: whether the drug class fits, whether this specific product and dose path fit, and whether current symptoms mean the plan needs to slow down or change. Around realistic weight expectations, outcome trials and standards of care can frame the metabolic context, yet they do not cancel label-based warnings or individualized screening. [6]
What this changes at the visit
When a weight-loss plateau is the reason for the visit, bring the exact product name, dose, last dose date, dose-escalation stage, bowel pattern, nausea or reflux severity, hydration status, protein intake, diabetes medicines, kidney history, gallbladder history, thyroid-cancer family history, surgery plans, and any compounded-product details. With the maintenance phase, the clinician does not need a meticulous journal. For realistic weight expectations, the clinician just needs enough signal to sort routine monitoring from a slower titration, a medication switch, or a red-flag evaluation.
What to ask a clinician
Ask:
- Is this a normal plateau, a medication-access problem, or a tolerability problem?
- Are my dose, side effects, protein intake, resistance training, sleep, and other medicines being reviewed together?
- What would make maintenance success enough for now?
- What red flags would make us slow escalation, pause, switch, or evaluate another cause?
- If I stop, what is the regain-prevention plan?
Evidence limits
The evidence is limited when plateau and maintenance data are used to promise one timeline for every patient. Semaglutide and tirzepatide trials show that continued treatment, withdrawal, and maintenance planning matter, but they do not decide whether one woman's plateau is dose tolerance, access, sleep, medication interaction, low intake, or true maintenance. [1] [2] [4]
Bottom line
After menopause, a glucagon-like peptide-1 plateau should trigger review, not shame.
The clinician should look at dose, tolerability, nutrition, strength training, sleep, other medicines, and long-term access. A plateau may be the point where the plan becomes maintenance care.
Related reading:
- glucagon-like peptide-1 medicines Before Surgery After Menopause.
- Insulin Resistance After Menopause.
- Metformin After Menopause.
References
[1] Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4 https://pubmed.ncbi.nlm.nih.gov/36216945/
[2] Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945 https://pubmed.ncbi.nlm.nih.gov/38078870/
[3] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/nejmoa2206038 https://pubmed.ncbi.nlm.nih.gov/35658024/
[4] Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224 https://pubmed.ncbi.nlm.nih.gov/33755728/
[5] DailyMed. WEGOVY semaglutide injection and tablet prescribing information, revised June 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[6] DailyMed. ZEPBOUND tirzepatide injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b